BioWorld® - Medical Device Daily

More documents

Recommendations

Info

BioTime Inc. BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information KEY PERSONNEL: 6121 Hollis Street Emeryville CA 94608, US Phone: (510) 350-2940; Fax: (510) 350-2948 Web: www.biotimeinc.com; E-mail: contacts@biotimemail.com Judith Segall; VP, Technology and member of office of president Hal Sternberg, Ph.D.; VP, R&D and member of office of president Harold Waitz, Ph.D.; VP, Regulatory and member of office of president Jeffrey B. Nickel, Ph.D.; VP, Business Development and Marketing Stephen Seinberg; CFO EMPLOYEES: 9 employees, 4 Ph.D.s HISTORY: Founded in November 1990 Began biotech R&D in 1991 FACILITIES: 5,244 sq. ft. of leased space in Emeryville, Calif. STOCK-FINANCIAL HISTORY: OTC BB--BTIM Subscription rights offering--283K shares at $20/share (2/97) 3:1 stock split (10/97) Revenue $903.200K (YE 05) compared to $688.377K (YE 04) Net loss (YE 05) compared to (YE 04) Loss per share (YE 05) compared to (YE 04) Average shares outstanding 17.903M (YE 05) compared to 17.454M (YE 04) Total assets $1.959M (YE 05) compared to $1.522M (YE 04) PRIVATE PLACEMENTS: Raised $1.8M in rights offer of stock and warrants (12/05) BUSINESS STRATEGY: Develop blood plasma volume expanders, blood replacement solutions for hypothermic surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment and other applications AGREEMENTS: Name Products Content of Agreement Date Abbott Hextend plasma- $40M licensing 4/97 Laboratories expanding product agreement--Abbott paid $1.4M licensing fee (7/97) Barrow blood substitute for low- research 1993 Neurological Institute of St. Joseph's Hospital temperature surgery agreement Baylor College of Hextend artificial blood research 12/95 Medicine (Houston, TX) plasma solution agreement Bronx Veterans blood replacement research 1993 Affairs Medical Center solutions agreement Davies Medical freeze-protecting research 1993 Center--Buncke solutions to preserve full agreement Clinic thickness skin grafts McGaw Inc. Hextend production agreement 12/94 Metropolitan blood replacement research 1993 Hospital solution agreement Mt. Sinai Medical blood replacement research 1993 Center solution agreement Summit Hextend and PentaLyte development 12/05 Pharmaceuticals International Corp. for the Japanese market agreeement RESEARCH & DEVELOPMENT: Synthetic solutions that can be used as blood plasma volume expanders, blood replacement solutions during hypothermic surgery, and organ preservation solutions Copyright ©2006 AHC Media ® 90
BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information PRODUCTS ON MARKET: Hextend® blood substitute solution for low-temperature surgical procedures PRODUCTS IN DEVELOPMENT: Name Status Pentalyte in Phase II clinicals Hetacool in discovery Hetafreeze in discovery BioVectra dcl 16 McCarville Street Charlottetown PE--C0A 1H0, Canada Phone: (902) 566-9116; Fax: (902) 628-2045 Toll-free phone: (866) 883-2872 Web: www.biovectra.com E-mail: info@biovectra.com KEY PERSONNEL: Dr. Rejis Duffy; Chairman Ron Keefe; President Dale Zajicek; COO Gordon Rogers; CFO Dr. Gary R. Reid; VP, R&D Dr. Tibor Breining; Director, R&D Dr. Richard Bethell; Sr. Scientist Patrick Duffy; Purchasing Manager EMPLOYEES: 200+ employees, 7 Ph.D.s HISTORY: Founded and began biotech R&D in 1970 STOCK-FINANCIAL HISTORY: Privately held SUBSIDIARIES/DIVISIONS: Diagnostic Chemicals Limited BUSINESS STRATEGY: Custom manufacturing Provide bioprocessing reagents and services Bioxel Pharma Inc. 3075 Chemin des Quatre-Bourgeois, Suite 440 Sainte-Foy G1W 4Y5, Canada Phone: (418) 654-9666; Fax: (418) 654-9655 Web: www.bioxelpharma.com E-mail: bioxelpharma@bioxelpharma.com KEY PERSONNEL: Andre P. Boulet, Ph.D.; Chairman Pascal Delmas; CEO and President Louis McGuire; VP, Finance and CFO Paul Metz; Exec. VP, Commercial Operations Andre Lalonde; VP, Biomass Louis Estaque, Ph.D.; VP, Production EMPLOYEES: 10 employees HISTORY: Founded in 1995 STOCK-FINANCIAL HISTORY: TSX--BIP Public offering--13.571M common shares at $0.70/share, $9.5M (3/03) Revenue $1.834M (YE 05) compared to $2.352M (YE 04) Net loss (YE 05) compared to (YE 04) Loss per share (YE 05) compared to (YE 04) Average shares outstanding 55.699M (YE 05) compared to 47.396M (YE 04) Total assets $9.587M (YE 05) compared to $13.004M (YE 04) Copyright ©2006 AHC Media ® 91
Page 1 and 2:
BioWorld ® INDUSTRIAL BIOTECHNOLGY
Page 3 and 4:
BioWorld Industrial Biotechnology S
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40: Applera Corp. BioWorld Industrial B
Page 41 and 42: BioWorld Industrial Biotechnology S
Page 89: BioWorld Industrial Biotechnology S
Page 99 and 100: CABI BioWorld Industrial Biotechnol
Page 107 and 108: Cargill Inc. BioWorld Industrial Bi
Page 109 and 110: Ceapro Inc. BioWorld Industrial Bio
Page 133 and 134: Digene Corp. BioWorld Industrial Bi
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
EvoGenix Ltd. BioWorld Industrial B
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Galderma SA BioWorld Industrial Bio
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Hercules Inc. BioWorld Industrial B
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Iogen Corp. BioWorld Industrial Bio
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Lake States BioWorld Industrial Bio
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Paprican BioWorld Industrial Biotec
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Primm S.R.L. BioWorld Industrial Bi
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Prokaria ehf BioWorld Industrial Bi
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Recordati SpA BioWorld Industrial B
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Symbio BioWorld Industrial Biotechn
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
UVP Inc. BioWorld Industrial Biotec
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
YMC Co. Ltd. BioWorld Industrial Bi
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
show all

BioWorld® - Medical Device Daily

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?